Crossref
Vedolizumab – a novel anti-integrin antibody with high gastrointestinal selectivity
Gastroenterologie a hepatologie · 2014
DOI: 10.14735/amgh2014481 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastroenterologie a hepatologie, 2014. Verfasst von Martin Bortlík. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Bortlík, M. (2014). Vedolizumab – a novel anti-integrin antibody with high gastrointestinal selectivity. Gastroenterologie a hepatologie. https://doi.org/10.14735/amgh2014481
Vancouver
Bortlík M. Vedolizumab – a novel anti-integrin antibody with high gastrointestinal selectivity. Gastroenterologie a hepatologie. 2014. doi:10.14735/amgh2014481
BibTeX
@article{Bortlk2014,
author = {Bortlík, Martin},
title = {Vedolizumab – a novel anti-integrin antibody with high gastrointestinal selectivity},
journal = {Gastroenterologie a hepatologie},
year = {2014},
doi = {10.14735/amgh2014481}
}
EUVIMED